Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Lilly CEO Sees Donanemab’s Accelerated Nod in Coming Months, Japan Approval in 2024
November 9, 2022
-
REGULATORY MOF Proposes Transition to Normal Framework for COVID Vaccines, Therapeutics
November 8, 2022
-
REGULATORY MOF Renews Its Push for Full Drug Price Revision in FY2023
November 8, 2022
-
BUSINESS Cartagena Act Stalls Gene Therapy Development in Japan; Pfizer, FIRM Calling for Deregulation
November 7, 2022
-
BUSINESS Moderna Forging Ahead with mRNA Vaccine Programs for Difficult Viruses; CMV, HIV Jabs in Pipeline: CSO
November 4, 2022
-
ORGANIZATION Priority of Japan Investment Lowered at 27% of Multinational Firms: JPMA Poll
November 2, 2022
-
BUSINESS Average Price Gap for 2023 Revision Looks to Be a Bit Lower than 7.6%: Wholesalers
November 1, 2022
-
REGULATORY Aricept’s Lewy Body Dementia Indication to Be Modified after Post-Launch Trial Miss
October 31, 2022
-
REGULATORY Ex-Bureaucrats, Academics Trade Barbs over Macroeconomic Indexing; Will MOF Allow Rise in Drug Cost?
October 28, 2022
-
ORGANIZATION Japan Needs New Forum for Top-Level Dialogue Including Global CEOs: PhRMA Chair
October 28, 2022
-
BUSINESS Cancer-Savvy New CMO Eager to Extend Astellas’ Oncology Portfolio, Bag Speedy Approval
October 28, 2022
-
REGULATORY Chuikyo to Discuss 2023 Off-Year Re-Pricing with Its Implementation as Premise: MHLW
October 27, 2022
-
REGULATORY LDP to Launch Lawmakers’ League on Medical Adhesive Patches
October 27, 2022
-
REGULATORY Pfizer Assesses Cancer Risk from Amoxan as “Acceptable” at “1 in 200,000 People”
October 26, 2022
-
REGULATORY Commodity Prices Are Rising, That’s Why Full Drug Re-Pricing Needed in 2023: MOF Official
October 25, 2022
-
REGULATORY Moderna’s BA.4/5 COVID Jab Up for PAFSC Review on Oct. 31
October 25, 2022
-
BUSINESS Genmab to Branch Out into 2nd Disease Area beyond Cancer, Specifics to Be Unveiled Next Year: CEO
October 24, 2022
-
ORGANIZATION Over 80% of Wholesaler Reps Say Shipment Adjustments Take Up Most of Their Time: Survey
October 21, 2022
-
REGULATORY With Shortened Interval, Omicron Booster Likely to Cover 18 Million More People by Month-End
October 21, 2022
-
BUSINESS Kyowa Kirin Assigns Bone Metabolism Specialists to Promote Crysvita in Japan
October 20, 2022
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…